Methods:In this phase 2b,double-blind,randomized,placebo-controlled trial,patients with noncirrhotic,highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo o...Methods:In this phase 2b,double-blind,randomized,placebo-controlled trial,patients with noncirrhotic,highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks.The primary end point was a decrease of at least 2 points in the SAF-A score(the activity part of the Steatosis,Activity,Fibrosis[SAF]scoring system that incorporates scores for ballooning and inflammation)without worsening of fibrosis;SAF-A scores range from 0 to 4,with higher scores indicating more-severe disease activity.Secondary end points included resolution of NASH and regression of fibrosis.展开更多
Autophagy is a mechanism involved in cellular homeostasis under basal and stressed conditions delivering cytoplasmic content to the lysosomes for degradation to macronutrients.The potential role of autophagy in diseas...Autophagy is a mechanism involved in cellular homeostasis under basal and stressed conditions delivering cytoplasmic content to the lysosomes for degradation to macronutrients.The potential role of autophagy in disease is increasingly recognised and investigated in the last decade.Nowadays it is commonly accepted that autophagy plays a role in the hepatic lipid metabolism.Hence,dysfunction of autophagy may be an underlying cause of non-alcoholic fatty liver disease.However,controversy of the exact role of autophagy in the lipid metabolism exists:some publications report a lipolytic function of autophagy,whereas others claim a lipogenic function.This review aims to give an update of the present knowledge on autophagy in the hepatic lipid metabolism,hepatic insulin resistance,steatohepatitis and hepatic fibrogenesis.展开更多
文摘Methods:In this phase 2b,double-blind,randomized,placebo-controlled trial,patients with noncirrhotic,highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks.The primary end point was a decrease of at least 2 points in the SAF-A score(the activity part of the Steatosis,Activity,Fibrosis[SAF]scoring system that incorporates scores for ballooning and inflammation)without worsening of fibrosis;SAF-A scores range from 0 to 4,with higher scores indicating more-severe disease activity.Secondary end points included resolution of NASH and regression of fibrosis.
基金Supported by Fund for Scientific Research(FWO)-Flanders(11J9513N,G007412N,G044312N,1802514N),to Kwanten WJ,Martinet W and Francque SM
文摘Autophagy is a mechanism involved in cellular homeostasis under basal and stressed conditions delivering cytoplasmic content to the lysosomes for degradation to macronutrients.The potential role of autophagy in disease is increasingly recognised and investigated in the last decade.Nowadays it is commonly accepted that autophagy plays a role in the hepatic lipid metabolism.Hence,dysfunction of autophagy may be an underlying cause of non-alcoholic fatty liver disease.However,controversy of the exact role of autophagy in the lipid metabolism exists:some publications report a lipolytic function of autophagy,whereas others claim a lipogenic function.This review aims to give an update of the present knowledge on autophagy in the hepatic lipid metabolism,hepatic insulin resistance,steatohepatitis and hepatic fibrogenesis.
